Georgia's Online Cancer Information Center

Multiple Myeloma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Multiple Myeloma
Cancer Type = Multiple Myeloma
There are currently 36 active Multiple Myeloma clinical trials in Georgia.
4.
A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03374085
Protocol IDs
CC-92480-MM-001
NCI-2018-00132
U1111-1205-3650
2017-001236-19
Treatment Sites (1)
Emory Clinic
Atlanta
5.
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
Treatment Sites (1)
12.
NCORP Trial
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03651128
Protocol IDs
BB2121-MM-003
NCI-2018-02057
U1111-1217-9988
2018-001023-38
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03650491
Protocol IDs
FOR46-002
NCI-2018-02600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
Cancer Type
Multiple Myeloma, Unknown Primary
NCT ID
NCT02004275
Protocol IDs
A061202
NCI-2013-01702
CALGB-A061202
Treatment Sites (1)
20.
An Open-Label, Single Arm, Phase 2 Study of Carfilzomib Maintenance Therapy in Subjects Previously in Enrolled Carfilzomib Treatment Protocols
Cancer Type
Multiple Myeloma
NCT ID
NCT00884312
Protocol IDs
PX-171-010
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Comparison of Quality of Bone Marrow Biopsy and Patient Convenience and Pain Control by a Battery Powered Drill versus Conventional Methods in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma
NCT ID
NCT03078452
Protocol IDs
Winship2656-14
NCI-2017-00308
IRB00075658
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Consolidation and Maintenance Therapy with Carfilzomib, Pomalidomide and Dexamethasone (CPD) in High-Risk Myeloma Patients: A Phase 2 Study with a Safety Run-In
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03756896
Protocol IDs
Winship4101-17
NCI-2017-02052
IRB00097882
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
Enhancing Anti-Myeloma Vaccine Response after Autologous Stem Cell Transplantation
Cancer Type
Multiple Myeloma
NCT ID
NCT02700841
Protocol IDs
WINSHIP2905-15
NCI-2015-00743
IRB00079982
24.
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed / Refractory Multiple Myeloma Patients: A Phase 1b Trial
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03770260
Protocol IDs
10249
10249
NCI-2018-03121
Treatment Sites (2)
26.
PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03605719
Protocol IDs
Winship4398-18
NCI-2018-01217
IRB00104234
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Phase 1 / 2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03761108
Protocol IDs
R5458-ONC-1826
NCI-2019-02952
2018-003188-78
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases from Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
Phase II Trial of Ixazomib and Dexamethasone versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Cancer Type
Multiple Myeloma
NCT ID
NCT02765854
Protocol IDs
MMRC060
NCI-2016-00043
IRB00077815
Treatment Sites (2)
Gordon Hospital
Calhoun
Lanell Jacobs
706-879-5852
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
Pilot Study of Oral Rifaximin in Patients with Monoclonal Gammopathy
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03267888
Protocol IDs
RAD4106-17
NCI-2017-01485
IRB00097324
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT02101944
Protocol IDs
9603
9603
NCI-2014-00643
2014C0091
NCI-9603
OSU-14031
14031
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCT ID
NCT01838512
Protocol IDs
CA204-008
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
34.
Protocol H125001: An Open-Label Phase 1 / 2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCT ID
NCT03430011
Protocol IDs
H125001
NCI-2018-00365
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
36.
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (2)
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.